Cargando…

HUNK Signaling in Metastatic Breast Cancer

Once metastatic disease has occurred, there is no cure for breast cancer. Consequently, identifying factors that promote and support breast cancer metastasis is critical for understanding how to pharmacologically target this process. Hormonally up-regulated neu-associated kinase (HUNK) is a serine/t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dilday, Tinslee, Ramos, Nicole, Yeh, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Research Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343571/ https://www.ncbi.nlm.nih.gov/pubmed/32676513 http://dx.doi.org/10.18632/oncoscience.504

Ejemplares similares

HUNK Gene Alterations in Breast Cancer
por: Ramos-Solis, Nicole, et al.
Publicado: (2022)

HUNK phosphorylates EGFR to regulate breast cancer metastasis
por: Williams, Carly B., et al.
Publicado: (2019)

Correction: HUNK phosphorylates EGFR to regulate breast cancer metastasis
por: Williams, Carly B., et al.
Publicado: (2021)

Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer
por: Phelps-Polirer, Kendall, et al.
Publicado: (2016)

HUNK Phosphorylates Rubicon to Support Autophagy
por: Zambrano, Joelle N., et al.
Publicado: (2019)

Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors
por: Yeh, Elizabeth S., et al.
Publicado: (2014)

Hunk/Mak-v is a negative regulator of intestinal cell proliferation
por: Reed, Karen R, et al.
Publicado: (2015)

Core-Fucosylated Tetra-Antennary N-Glycan Containing A Single N-Acetyllactosamine Branch Is Associated with Poor Survival Outcome in Breast Cancer
por: Herrera, Harmin, et al.
Publicado: (2019)

Staurosporine, an inhibitor of hormonally up-regulated neu-associated kinase
por: Zambrano, Joelle N., et al.
Publicado: (2018)

Therapeutic potential of chemokine signal inhibition for metastatic breast cancer
por: Kitamura, Takanori, et al.
Publicado: (2015)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
por: Lebert, Julie, et al.
Publicado: (2022)

FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond
por: Hildebrandt, Malene Grubbe, et al.
Publicado: (2019)

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
por: Tanguy, Marie-Laure, et al.
Publicado: (2018)

Precision health for breast cancer metastasis: biomaterial scaffolds as an engineered metastatic niche to define, study, and monitor metastatic progression
por: Bushnell, Grace G., et al.
Publicado: (2019)

HUNK inhibits epithelial-mesenchymal transition of CRC via direct phosphorylation of GEF-H1 and activating RhoA/LIMK-1/CFL-1
por: Han, Xiaoqi, et al.
Publicado: (2023)

Stem Cells and Metastatic Cancer: Fatal Attraction?
por: Fodde, Riccardo
Publicado: (2006)

Oxidants, antioxidants and the current incurability of metastatic cancers
por: Watson, Jim
Publicado: (2013)

Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm
por: Olivier, Timothee, et al.
Publicado: (2021)

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms
por: Wheler, Jennifer J., et al.
Publicado: (2014)

The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy
por: Kast, Richard E, et al.
Publicado: (2017)

DDT and Breast Cancer
por: Tarone, Robert E.
Publicado: (2008)

The connection between lymphangiogenic signalling and prostaglandin biology: A missing link in the metastatic pathway
por: Karnezis, Tara, et al.
Publicado: (2012)

NF-κB Signaling Is Regulated by Fucosylation in Metastatic Breast Cancer Cells
por: Doud, Emma H., et al.
Publicado: (2020)

Association of Hypertension and Breast Cancer: Antihypertensive Drugs as an Effective Adjunctive in Breast Cancer Therapy
por: Fan, Yuanyuan, et al.
Publicado: (2022)

DDT and Breast Cancer Trends
por: Tarone, Robert E.
Publicado: (2008)

Breast cancer survivorship in India
por: D’Souza, Rebecca Brian, et al.
Publicado: (2021)

GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapies
por: Nguyen, Khoa, et al.
Publicado: (2022)

Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer
por: Vidula, Neelima, et al.
Publicado: (2021)

Immunotherapy for early triple negative breast cancer: research agenda for the next decade
por: Tarantino, Paolo, et al.
Publicado: (2022)

The Gut Microbiome and Metastatic Renal Cell Carcinoma
por: Meza, Luis, et al.
Publicado: (2023)

Birth Size and the Pathogenesis of Breast Cancer
por: Lagiou, Pagona, et al.
Publicado: (2008)

Breast Cancer Environment Centers and Advocacy
por: Wolff, Mary S., et al.
Publicado: (2011)

Progress in targeted therapy for breast cancer
por: Ju, Jie, et al.
Publicado: (2018)

An alternative model for (breast) cancer predisposition
por: Teugels, Erik, et al.
Publicado: (2017)

Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer
por: Renzulli, Joseph F, et al.
Publicado: (2015)

Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer
por: Yuan, Peng, et al.
Publicado: (2017)

Using Genetic Testing at Cancer Diagnosis for Breast Cancer Control
por: Sun, Li, et al.
Publicado: (2022)

Deconstructing Signaling Pathways in Cancer for Optimizing Cancer Combination Therapies
por: Yamaguchi, Ryuji, et al.
Publicado: (2017)

Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
por: Labadie, Brian W, et al.
Publicado: (2022)

Melanocytic Nevi as Biomarkers of Breast Cancer Risk
por: Fuhrman, Barbara, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tmpeq9onu4dbd5tbma670plnfg